Impact of Medicaid Expansion on Survival in Colorectal Cancer with Liver Metastasis: A Population-Based Analysis

MedXY Editorial Team•Oct 5, 2026•Gastroenterology

Medicaid expansion (ME) under the Affordable Care Act is linked with a significant reduction in 3-year disease-specific mortality among patients under 65 years diagnosed with colorectal cancer and synchronous liver metastasis (CRLM).
The mortality benefit was most pronounced in patients undergoing liver metastasectomy, suggesting improved access to complex multidisciplinary surgical and systemic oncologic care.
Decreased mortality was observed starting 2-3 years after Medicaid expansion and persisted beyond 6 years, despite no significant increase in liver surgery rates.
ME may enhance continuity and quality of complex cancer care by facilitating access to systemic therapies and multidisciplinary management in populations historically underserved.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Medicaid expansion (ME) under the Affordable Care Act is linked with a significant reduction in 3-year disease-specific mortality among patients under 65 years diagnosed with colorectal cancer and synchronous liver metastasis (CRLM).
The mortality benefit was most pronounced in patients undergoing liver metastasectomy, suggesting improved access to complex multidisciplinary surgical and systemic oncologic care.
Decreased mortality was observed starting 2-3 years after Medicaid expansion and persisted beyond 6 years, despite no significant increase in liver surgery rates.
ME may enhance continuity and quality of complex cancer care by facilitating access to systemic therapies and multidisciplinary management in populations historically underserved.